Choose a folder
DISCOVER at EASD 2019
The DISCOVER team had a very enjoyable 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), 16 – 20 September in Barcelona, Spain.
The congress provided a wonderful opportunity to share our findings from the DISCOVER study programme with the wider scientific community.
Dr Suzanne Arnold presented a poster on the incidence and prevalence of chronic kidney disease (CKD) in DISCOVER patients (Khunti K et al. Poster 1008. Type 2 diabetes and chronic kidney disease: insights from DISCOVER). CKD was assessed by tracking patients’ estimated globular fitration rate (eGFR) over the first two years of the study. Among the patients with eGFR data recorded at baseline, 54.0% had CKD of stage 2 or above (76.8% stage 2).
Later stage CKD was associated with lower use of metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium–glucose cotransporter-2 (SGLT-2) inhibitors, and higher use of sulfonylureas. Of patients who had eGFR measurements recorded at baseline and during follow-up, disease progressed by at least one stage in 17.4%.
Two encore posters were presented that had previously been shown at the 79th Scientific Sessions of the American Diabetes Association (ADA). The first of these was given by Professor Antonio Nicolucci (Nicolucci A et al. Poster 353. Changes in HbA1c and treatment in the second year following initiation of second-line therapy in people with type 2 diabetes: the global DISCOVER study). Of patients with available data, 17.0% changed their treatment during the second year of the DISCOVER study. For most patients, this change involved treatment intensification.
The second encore poster was presented by Professor Marilia Gomes (Gomes M et al. Poster 815. Socioeconomic factors associated with poor glycaemic control (HbA1c ≥ 9.0%) in people with type 2 diabetes: the DISCOVER study). DISCOVER patients living in lower-middle-income countries were shown to be less likely to have HbA1c levels recorded during treatment compared to patients from high-income countries, and those patients who did have HbA1c levels recorded were more likely to have an HbA1c level ≥ 9.0%.
Dr Arnold also delivered an informative oral presentation on the incidence and prevalence of heart failure in DISCOVER patients, which was also based on a poster previously presented at ADA (Arnold S et al. Presentation 195. Type 2 diabetes and heart failure: insights from the DISCOVER study). The analyses showed that the prevalence of heart failure among DISCOVER patients was 1.9% at baseline, increasing to 2.5% by the end of year 2.
Following these engaging presentations, the DISCOVER Scientific Committee met to discuss data collection and future DISCOVER publications. The committee members are looking forward to seeing the final study data later this year, and are excited to see how these results will help to improve the treatment of type 2 diabetes worldwide.